Cargando…
Effect of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Cerebral vasospasm is the most important potentially treatable cause of mortality and morbidity following aneurysmal subarachnoid hemorrhage (aSAH). Clazosentan, a selective endothelinreceptor antagonist, has been suggested to help reduce the incidence of vasospasm in patients with aSAH....
Autores principales: | Wang, Xiang, Li, Yi-Ming, Li, Wei-Qing, Huang, Cheng-Guang, Lu, Yi-Cheng, Hou, Li-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474756/ https://www.ncbi.nlm.nih.gov/pubmed/23082215 http://dx.doi.org/10.1371/journal.pone.0047778 |
Ejemplares similares
-
Effects of clazosentan, cilostazol, and statins on aneurysmal subarachnoid hemorrhage: A protocol for systematic review and meta-analysis
por: He, Junfang, et al.
Publicado: (2020) -
The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
por: Bruder, Nicolas, et al.
Publicado: (2022) -
Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials
por: Ma, Junpeng, et al.
Publicado: (2012) -
Effects of statins-use for patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials
por: Su, Shao-Hua, et al.
Publicado: (2014) -
Timing of operation for poor-grade aneurysmal subarachnoid hemorrhage: study protocol for a randomized controlled trial
por: Zhang, Qiao, et al.
Publicado: (2013)